Information is current as of 3/1/2022, updates are made on a quarterly basis
* Candidate received accelerated approval in the U.S., confirmatory studies required
** Roche has the exclusive right to launch and commercialize SRP-9001 outside the United States
*** Gene therapy and PPMO
For more information about our pipeline, please contact Sarepta’s Patient Affairs team at [email protected].